Low-density lipoprotein receptor-related protein 5 gene polymorphisms and genetic susceptibility to abdominal aortic aneurysm  by Galora, Silvia et al.
From
Fl
th
“T
sit
This
to
H
Auth
Add
Rep
C
It
The
to
m
0741
Cop
http
106Low-density lipoprotein receptor-related protein
5 gene polymorphisms and genetic susceptibility
to abdominal aortic aneurysm
Silvia Galora, BS,a Claudia Saracini, PhD,a Anna Maria Palombella, BS,a Giovanni Pratesi, MD,b
Raffaele Pulli, MD,c Carlo Pratesi, MD,c Rosanna Abbate, MD,a and Betti Giusti, PhD,a Florence
and Rome, Italy
Background: Previous data showed decreased low-density lipoprotein receptor-related protein 5 (LRP5) gene expression
in peripheral blood cells of abdominal aortic aneurysm (AAA) patients and an association between decreased expression of
LRP5 and increased lipoprotein (a) [Lp(a)] levels in AAA. LRP5 gene is involved in bone, lipid, and glucose metabolism,
and experimental studies showed that atherosclerotic lesions of ApoE:LRP5 double knockout mice were wthreefold
greater than those in ApoE-knockout mice and were characterized by features of advanced atherosclerosis, with
remarkable accumulation of foam cells and destruction of the internal elastic lamina. The aim of this study was to evaluate
the role of polymorphisms in LRP5 gene in determining genetic susceptibility to AAA.
Methods: A total of 423 AAA patients and 423 controls comparable for sex and age were genotyped for seven
polymorphisms within the LRP5 (rs667126, rs3736228, rs4988300, rs3781590, rs312016, rs556442, rs627174) by
TaqMan approach.
Results: Two polymorphisms were signiﬁcantly associated with AAA: rs4988300, carriers of the T allele in AAA (74.0% vs
65.3% in controls; P[ .007); and rs3781590, carriers of the T allele in AAA (66.5% vs 57.4% in controls; P[.009). At
the multiple logistic regression analysis, adjusted for age, sex, dyslipidemia, hypertension, smoking habit, and chronic
obstructive pulmonary disease, rs4988300 and rs3781590 polymorphisms remained signiﬁcant and independent
determinants of AAA (OR, 1.62; 95% CI, 1.02-2.56; P [ .040, and OR, 1.83; 95% CI, 1.17-2.85; P [ .008,
respectively). We conﬁrmed that AAA patients had signiﬁcantly higher Lp(a) levels than control subjects (180.0 mg/L vs
107.6 mg/L; P < .0001). The prevalence of patients with Lp(a) levels $300 mg/L was signiﬁcantly higher in patient
carriers of the rs4988300 T allele than in wild-type patients (42.6% vs 30.8%; P [ .048).
Conclusions: Present data have identiﬁed rs4988300 and rs3781590 LPR5 polymorphisms as independent genetic
markers of AAA and underlined the need to concentrate our effort in studying the role of these markers in AAA and of
LRP5 gene in Lp(a) catabolism and AAA pathophysiology. (J Vasc Surg 2013;58:1062-8.)
Clinical Relevance: This work identiﬁes two polymorphisms in LRP5 gene (rs4988300 and rs3781590) as genetic markers
of abdominal aortic aneurysm (AAA) and underlines the need to concentrate our effort in studying the role of thesemarkers
in AAA and of LRP5 gene in Lp(a) catabolism and AAA pathophysiology. These data are fundamental in developing future
diagnostic or prognostic scores based on clinical, bio-humoral, genetic, proteomic, and imaging data to be applied in
everyday clinical practice to improve the management of these high-risk patients considering their characteristics and
pathophysiologic complexity.Abdominal aortic aneurysm (AAA) represents a severe dilation of the aortic wall. The prevalence of AAA is
chronic degenerative condition associated with atheroscle-
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2w5% in men and w1% in women aged >60 years. AAA
is estimated to be the 10th most common cause of
mortality and is responsible for >2% of all deaths.1,2 The
pathogenesis of this complex disorder is the result of inter-
actions among multiple genes and environmental factors,
but it has not yet been completely clariﬁed.3,4 A key mech-
anism in AAA pathogenesis and progression is the proteo-
lytic degradation of the aortic wall. Increased elastase and
collagenase activities have been found in aortic aneurysms,
and both have been positively correlated with diffuse alter-
ations of extracellular matrix (ECM) composition and
aneurysm size.3
Recently, our group, by evaluating global gene expres-
sion proﬁles in AAA patients and controls, demonstrated
the alteration of several genes involved in the biological
process of lipid metabolism.5 Among the differentially
expressed genes associated with lipid metabolism, we
observed, in particular, a decreased expression of the low-
density lipoprotein receptor-related protein 5 (LRP5)
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that work,5 we also hypothesized that LRP5 gene could
play a role in the catabolism of lipoprotein (a) [Lp(a)],
a well-known atherothrombotic risk factor.6 Indeed,
Lp(a) levels were signiﬁcantly higher in AAA patients
compared with controls, and they were related to the
expression of LRP5 gene. Patients with Lp(a) levels
$300 mg/L showed a statistically signiﬁcant decreased
expression of LRP5 gene compared with patients with
Lp(a) levels <300 mg/L.5
The LRP5 gene is located on the long arm of chromo-
some 11 at position 13.4 and encodes for a protein with
a role of receptor for low-density lipoprotein; this protein
is also known as a coreceptor with frizzled-4 in the Wnt
signaling pathway (OMIM *603506).
The LRP5 protein has a pivotal role in the develop-
ment and maintenance of different tissues and is also
involved in establishing a blood supply to the retina and
the inner ear.7 Additionally, this protein regulates bone
mineral density.8,9 In particular, loss of function genetic
variations of this gene are associated with osteoporosis
pseudoglioma syndrome (OPPG, OMIM #259770) and
with the onset of diseases related to low bone density.10-17
The LRP5 gene involvement in glucose and lipid metabo-
lism was more recently hypothesized but not yet accepted
and conﬁrmed.18
Data obtained in a mouse model indicate that by
feeding double knock-out mice with LRP5 and ApoE
genes with a traditional diet, it is possible to observe plasma
cholesterol levels greater than 60% compared with knock-
out mice only for the ApoE gene. The histologic analysis
of arterial tissue also shows a signiﬁcant accumulation of
advanced atherosclerotic disease with foam cells and
destruction of internal elastic lamina and signiﬁcantly
more severe atherosclerotic lesions in double knockout
mice (ApoE:LRP5) compared with only knock-out mice
for the ApoE gene. These data suggest that the LRP5
gene is an intermediary in the ApoE-dependent and -inde-
pendent catabolism of plasma lipoproteins.19
In addition, in a mouse model, the involvement of
LRP5 gene in the metabolism of cholesterol and glucose
was shown20 observing in knock-out mice for the LRP5
gene that this gene is required for proper clearance of
remnants of chylomicrons and secretion of glucose-
induced insulin from pancreatic islets. LRP5 polymor-
phisms have been associated with blood pressure21 or
obesity.22 The aim of the present study was to evaluate
the role of single nucleotide polymorphisms (SNPs) in
LRP5 gene in determining genetic susceptibility to AAA.
METHODS
Study population. We enrolled 423 consecutive
patients with AAA referred to the Vascular Surgery Unit
of the University of Florence. Familial and inﬂammatory
AAAs were excluded from the study. Familial genetic
patterns might inﬂuence the predictive value of the gene
polymorphisms that are included in this study. In several
studies, some differences were reported between AAApatients with or without a ﬁrst-degree relative with a history
of AAA (ie, higher prevalence of male and higher mean
age in nonfamilial).23 Of the 604 consecutive AAA
patients, we excluded 151 (25%) familial atherosclerotic
AAA patients and 30 (4.97%) inﬂammatory AAA patients.
All controls had a negative personal and familial history of
AAA. Patients and control subjects included in this study
were previously investigated for polymorphisms involved in
the methionine metabolism24 and ECM remodeling.25
Deﬁnitions of the studied populations were reported in
previous papers.24,25 At the duplex scanning examination,
few controls (10/423) showed aortic diameters between 30
and 47 mm. We did not exclude these subjects, as this
situation could bemore representative of the general control
population, even if it could mitigate the signiﬁcance of the
association. In fact, we are looking for genetic markers
capable of identifying the risk of subjects of the general
population without a previous screening of the aortic
diameters. Therefore, we compared patients with AAA
referred to the Vascular Surgery Unit of the University of
Florence for surgery with the control subjects.
Patients and controls gave informed consent and the
study was approved by the Ethical Committee.
DNA extraction. Genomic DNA was isolated from
venous peripheral blood by using FlexiGene kit (QIAGEN,
Hilden, Germany).
Genotyping. We studied seven polymorphisms in the
LRP5 gene, chosen by literature data because of their associ-
ation with bone characteristic, obesity, and hypercholesterol-
emia phenotypes.10-17,22 Information on polymorphisms
was assessed in a single nucleotide polymorphism database
(dbSNP) NCBI (http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db¼snp&cmd¼search&term¼) and ENSEMBL
database (http://www.ensembl.org/index.html). InTable I,
characteristics of the seven selected polymorphisms are
reported.
Data analysis. Statistical analysis was performed using
the SPSS package v. 19 (SPSS Inc, Chicago, Ill). Hardy-
Weinberg equilibrium (HWE) was evaluated by c2 test.
HWE is commonly used for quality control of genotyping.
It indicates inbreeding, population stratiﬁcation, and
systematic genotyping errors in unrelated individuals.
Genotype distributions were compared between AAA and
control groups or between patients with and without other
atherosclerotic localizations by c2 analysis. We assessed the
association between each polymorphism and AAA using
different genetic models. The dominant model compares
individuals with one or two rare alleles (heterozygotes þ
homozygotes) with the group of homozygous subjects.
The recessive model compares individuals with two
rare alleles (homozygotes) with the combined group
of heterozygous þ wild-type homozygous subjects. The
additive model assumes that there is a linear gradient in
risk among the three genotypes. Categorical variables are
expressed as frequencies and percentages. Unless otherwise
indicated, continuous data are given as median and range.
Post-hoc sample-size calculations indicated that a
number of 423 AAA patients and 423 controls have
Table I. Characteristics of the seven selected LRP5 polymorphisms
Chr
position
Nucleotide
substitution SNP ID
MAF
dbSNP
MAF
literature Region/function Assay numbera
68082403 A/G rs312016 T ¼ 0.325 T ¼ 0.41222 Intronic C____976104_10
68088831 T/G rs4988300 T ¼ 0.440 T ¼ 0.49522 Intronic C___3161759_10
68159152 C/T rs3781590 T ¼ 0.307 T ¼ 0.24722 Intronic C__27484274_10
68163514 C/T rs627174 C ¼ 0.160 C ¼ 0.87522 Intronic C___3161595_20
68177728 C/T rs667126 C ¼ 0.239 C ¼ 0.3210 Intronic C____780035_1_
68192690 A/G rs556442 C ¼ 0.279 C ¼ 0.27515 Exonic/Syn C___780057_1_
68201295 C/T rs3736228 T ¼ 0.138 T ¼ 0.13915 Exonic/Nonsyn C__25752205_10
Chr, Chromosome; LRP5, low-density lipoprotein receptor-related protein;MAF,minor allele frequency;Nonsyn, nonsynonymous; SNP ID, single nucleotide
polymorphism identity number; Syn, synonymous.
aLife Technologies LTD.
Table II. Demographic and clinical characteristics of
AAA patients and control subjects24,25
Characteristics
Controls
(n ¼ 423)
AAA
(n ¼ 423) P
Age, years (range) 72.0 (41-94) 73.5 (40-94) .651
Sex (male), No. (%) 366 (86.5) 376 (88.9) .295
Smoking habit, No. (%) 267 (63.1) 366 (86.5) <.0001
Diabetes, No. (%) 49 (11.6) 41 (9.7) .372
Hypertension, No. (%) 179 (42.3) 302 (71.4) <.0001
Dyslipidemia, No. (%) 50 (11.8) 195 (46.1) <.0001
COPD, No. (%) 66 (15.6) 311 (73.5) <.0001
CAD, No. (%) 107 (25.3) 163 (38.5) <.0001
CVD, No. (%) 38 (9.0) 111 (26.2) <.0001
POAD, No. (%) 67 (15.8) 118 (27.9) <.0001
Aortic diameter, mm
(range)
19 (12-47) 50 (31-98) <.0001
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary
disease; CAD, coronary heart disease; CVD, cerebrovascular disease;
POAD, peripheral occlusive arterial disease.
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centages of genotypes of 3% for rs312016, 76% for
rs4988300, 83% for rs3781590, 4% for rs627174, 8% for
rs667126, 7% for rs556442, and 7% for rs3736228. There-
fore, only the rs4988300 and rs3781590 polymorphisms
results were reported and discussed. Genotype distribu-
tions of the ﬁve polymorphisms with inadequate post-hoc
statistical power were reported in Supplementary Table I
(online only).
Comparisons of continuous variables between patients
and controls or among genotypes were performed by the
nonparametric Mann-Whitney or Kruskal-Wallis test.
Multiple logistic regression analysis was used to estimate
odds ratios (ORs) and 95% conﬁdence intervals (CIs) for
the risk of AAA. To evaluate if polymorphisms were inde-
pendently associated with AAA, multiple logistic regression
analyses were adjusted for traditional risk factors for AAA:
age, sex, hypertension, diabetes mellitus, dyslipidemia,
smoking habit, and chronic obstructive pulmonary disease
(COPD). The association between polymorphisms, which
were signiﬁcantly associated with AAA, and aortic diameter
was estimated by general linear model. To reduce type I
error, we applied the false discovery rate multiple testing
correction in all statistical analyses. A value of P < .05
was chosen as the cut-off level for statistical signiﬁcance.RESULTS
Table II shows demographic and clinical characteristics
of studied subjects (n ¼ 423 patients with AAA, and n ¼
423 control subjects). As expected, based on the selection
criteria of populations of cases and controls, no differences
were observed for age and sex between AAA patients and
controls (Table II). Instead, there were signiﬁcant differ-
ences in the prevalence of traditional cardiovascular risk
factors such as smoking habit, hypertension, dyslipidemia,
and COPD, as well as in the prevalence of other localiza-
tions of atherosclerotic disease (coronary artery disease,
cerebrovascular disease, and peripheral arterial obstructive
disease) (Table II). The median abdominal aortic diameter
of the 423 AAA patients was 50 (range, 31-98) mm
(Table II); 141 patients (33.3%) showed large abdominal
aortic aneurysms (>55 mm).Table III shows genotype distributions and minor
allele frequencies in patients with AAA and control subjects
of the rs4988300 and rs3781590 polymorphisms in the
LRP5 gene.
The genotype distributions of the polymorphisms
respected the HWE in patients and controls.
The genotype distributions of rs4988300 and
rs3781590 polymorphisms were signiﬁcantly different
between patients and controls (Table III). Carriers of the
T allele for rs3781590 and for rs4988300 LRP5 polymor-
phism had an increased risk of developing AAA, both
according to the additive and dominant model (Table III).
At the univariable logistic regression analysis, the polymor-
phism rs4988300 (allele T carrier status) showed an OR
equal to 1.52 (95% CI, 1.12-2.05; P ¼.007), and the poly-
morphism rs3781590 (allele T carrier status) had an OR
equal to 1.47 (95% CI, 1.11-1.96; P ¼ .008).
Upon multiple logistic regression analysis, with AAA
as the dependent variable and age, sex, hypertension,
diabetes mellitus, dyslipidemia, smoking habit, COPD,
and individual polymorphisms as independent variables,
the rs4988300 LRP5 polymorphism and the rs3781590
Table III. Genotype distribution and allele frequency of
the rs4988300 and rs3781590 LRP5 polymorphisms in
AAA patients and control subjects
LRP5
polymorphism
genotype
Patients
(n ¼ 423),
No. (%)
Control subjects
(n ¼ 423),
No. (%) P
rs4988300
TT 109 (25.8) 76 (18.0)
GT 204 (48.2) 200 (47.3) .004a
.007b
GG 110 (26.0) 147 (34.7)
Minor allele frequency T ¼ 0.499 T ¼ 0.417
rs3781590
CC 142 (33.5) 180 (42.5)
CT 213 (50.4) 181 (42.8) .025a
.009b
TT 68 (16.1) 62 (14.6)
Minor allele frequency T ¼ 0.426 T ¼ 0.361
AAA, Abdominal aortic aneurysm; LRP5, low-density lipoprotein receptor-
related protein.
aAccording to the additive model.
bAccording to the dominant model.
Table IV. ORs for the occurrence of AAA according to
rs4988300 and rs3781590 LRP5 polymorphisms
Variables OR (95% CI) P
LRP5 rs4988300
T allele
1.62 (1.02-2.56) .040
LRP5 rs3781590
T allele
1.83 (1.17-2.85) .008
Age 0.98 (0.95-1.00) .106
Gender 1.20 (0.59-2.45) .612
Hypertension 3.28 (2.15-5.02) <.0001
Dyslipidemia 5.77 (3.53-9.44) <.0001
Diabetes 0.75 (0.37-1.52) .433
Smoke habit 2.83 (1.63-4.93) <.0001
COPD 13.61 (8.67-21.35) <.0001
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; COPD, chronic
obstructive pulmonary disease; LRP5, low-density lipoprotein receptor-
related protein; OR, odds ratio.
Multiple logistic regression analysis adjusted for traditional cardiovascular
risk factors.
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risk factors for AAA (Table IV).
Hypertension, dyslipidemia, smoking habit, and COPD
were conﬁrmed to be signiﬁcant and independent determi-
nants of AAA (Table IV). Control subjects were enrolled
to be comparable for sex and age to the AAA patients, there-
fore they did not show a signiﬁcant association with AAA in
our model (Table IV).
Ten out of 423 controls showed aortic diameters
between 30 and 47 mm. However, the multiple logistic
regression analysis with the 10 control subjects with aortic
diameters >30 mm reclassiﬁed in the cohort of patients
showed similar results: rs4988300 LRP5 polymorphism
(OR, 1.51; 95% CI, 1.01-2.36; P < .049) and the
rs3781590 LRP5 polymorphism (OR, 1.89; 95% CI,
1.22-2.91; P ¼ .004).
The number of carriers of both the polymorphisms
rs3781590 and rs4988300 was signiﬁcantly different
between patients with AAA and control subjects (53.0%
AAA patients and 36.5% controls; P < .0001). At the
multiple logistic regression analysis, the status of combined
carriers of the two polymorphisms, rs4988300 and
rs3781590, showed the strongest association with AAA
(OR, 2.16; 95% CI, 1.41-3.29; P < .0001).
According to literature data, in the multiple logistic
regression model, we could also adjust for body mass index
(BMI), but we did not have data for some of the patients.
However, in controls, for which the data were available in
all subjects, no signiﬁcant differences in BMI were observed
between carriers of the T allele and homozygous wild-type
of the rs4988300 polymorphism (T allele carriers 27.97
[18.60- 36.57] K/m2 vs homozygous wild-type 27.14
[19.05-37.58] K/m2; P ¼ .202) or of the rs3781590
polymorphism (T allele carriers 27.59 [20.28-36.57]
K/m2 vs homozygous wild-type 27.08 (19.05-37.58)
K/m2; P ¼.202).Similar results were obtained in the subgroups of AAA
patients and controls without other localizations (coronary
artery disease, cerebrovascular disease, and peripheral
arterial occlusive disease) of atherosclerotic disease
(Supplementary Table II, online only).
We evaluated the effect of the two polymorphisms on
the diameter of the aorta. The rs4988300 and rs3781590
polymorphisms did not inﬂuence the aortic diameters
both in patients and controls (Supplementary Table III,
online only).
Serum Lp(a) levels were statistically higher in patients
with AAA compared with control subjects (AAA 180
[2-1773] mg/L vs controls 108 [2-1394] mg/L; P <
.0001) (Fig, A). We investigated whether polymorphisms
associated with AAA inﬂuence Lp(a) serum concentrations.
Although the levels of Lp(a) were not statistically higher in
carriers of the T allele of rs3781590 polymorphism and of
rs4988300 polymorphism, the prevalence of patients with
Lp(a) levels $300 mg/L is higher in patients carrying
the rs3781590 polymorphism (41.2% in carriers of the T
allele vs 35.0% in homozygous wild-type; P ¼ .266) and
statistically higher in patients carrying the rs4988300
polymorphism (42.6% in carriers of the T allele vs 30.8%
in homozygous wild-type; P ¼ .048) (Fig, B).
DISCUSSION
In the present work we identify for the ﬁrst time two
genetic variants of the LRP5 gene, rs4988300 (intron 1)
and rs3781590 (intron 7), as signiﬁcant and independent
risk factors for AAA. Moreover, we conﬁrm the association
of serum Lp(a) concentration with AAA and observe that
the prevalence of patients with Lp(a) levels $300 mg/L
was signiﬁcantly higher in patient carriers of the
rs4988300 T allele than in wild-type patients, suggesting
a possible role of LRP5 gene in the catabolism of Lp(a).
These data support and extend previous evidences from
our group suggesting an important role of the LRP5
gene in Lp(a) catabolism and in aneurysmal disease.5
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tion of the LRP5 genetic variants rs4988300 and
rs3781590 with AAA disease, both polymorphisms were
associated with other disease phenotypes.
In 733 Chinese unrelated subjects and 1873 Caucasian
subjects belonging to 405 families, linkage disequilibrium
analysis showed that LRP5 haplotype structures were
similar between Chinese and Caucasians.15 In this study,
rs3781590 polymorphism in block 4 was associated with
alteration of bone density of the hip and spine.15 In a study
conducted on Australian women (>55 and <80 years of
age), rs3781590 polymorphismwas the onemost associated
with alterations of bone mineral density.16 A genome-wide
association study on subjects of the Framingham Heart
Study identiﬁed rs4988300 LRP5 polymorphism as
a susceptibility locus for alteration of bone mass and geom-
etry.16 The rs4988300 polymorphism located in block 2
showed a signiﬁcant association with obesity and BMI.22
In particular, the T allele of rs4988300 polymorphism was
associated with an increased risk of obesity.22
Besides the last-mentioned evidence,22 further evidence
support the concept that LRP5 may be associated with the
etiology of obesity. A possible role for LRP5 in type 1 dia-
betes was found,26 as well as the crucial role of LRP5 in
cholesterol and glucose metabolism and type 2 diabetes.20
Since diabetes and obesity are highly correlated both genet-
ically and phenotypically,27 genes associated with the regu-
lation of diabetes could be also candidates for obesity. In
support of this thesis are data showing that in an animal
model the absence of LRP5 gene in mice knockout also
for ApoE induces severe hypercholesterolemia, defective
fat tolerance, and severe atherosclerosis.19
Furthermore, there is now a well-established, marked
genetic correlation between obesity phenotypes, such as
BMI, and osteoporosis phenotypes, such as the bone
mineral density, suggesting the existence of common
genetic factors contributing both to obesity and osteopo-
rosis.28-31Given the possible association, also in our population
of rs3781590 and rs4988300 polymorphisms with BMI,
BMI should be introduced in the model of multivariate
logistic regression analysis. A limitation of our study is
that in the logistic regression analysis, we could not adjust
for BMI because we did not have the data for part of the
patients. However, in control subjects, for whom the
data were available in all subjects, no signiﬁcant differences
in BMI were observed between subjects carrying the T
allele of p rs4988300 and rs3781590 polymorphism and
homozygous wild-type subjects. By identifying two impor-
tant genetic markers potentially easy to use in the clinical
practice, the data obtained in this work extend and conﬁrm
previous observations of an important role of the LRP5
gene in the onset of AAA.5,19,32
In fact, in a previous study, we observed a reduced
expression of LRP5 gene in venous peripheral blood cells
of AAA patients compared with controls5 and, although
not focused by the authors, a reduced expression of the
LRP5 gene was also observed in the aortic wall of AAA
patients.32 Moreover, experimental studies showed that
ApoE:Lrp5 double knockout mice developed severe
multiple atheromatous aortic lesions manifesting a hump
structure, which were associated with cholesterol deposits,
ﬁbrosis, and elastolysis, some even showing the destruction
of internal elastic lamina and the degenerative changes in
aortic smooth muscle.9
In a 2009 study, we demonstrated, for the ﬁrst time, an
association between the reduced expression of the LRP5
gene and increased levels of Lp(a) in patients with AAA,
which suggested a potential role of the LRP5 gene in the
catabolism of the Lp(a) (5). Different studies had previ-
ously shown that elevated Lp(a) serum levels play a role
in the genesis of systemic atherosclerosis, thrombosis and
related disorders and, in particular, in the onset of
AAA.33-35
In this study, we conﬁrmed the signiﬁcant association
of elevated serum Lp(a) concentrations with AAA.
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ated with AAA, rs3781590, and rs4988300 may inﬂuence
Lp(a) levels in patients. Although Lp(a) levels were not
statistically higher in carriers of the T allele of rs3781590
and rs4988300 polymorphisms, the prevalence of patients
with Lp(a) $300 mg/L was statistically higher in patients
carrying the rs4988300T allele. This data could be consis-
tent with previous observations concerning these two
polymorphisms, which showed rs3781590 polymorphism
primarily involved in the alteration of bone metabolism10,17
and rs4988300 polymorphism associated with both bone
and lipid metabolism.13 An imbalance between osteoblas-
togenesis and osteoclastogenesis, leading to either calciﬁca-
tion in stenotic/occlusive disease or destruction of the
ECM in aneurysmal disease has shown36 the association
of the rs3781590 polymorphism with AAA could be, at
least in part, due to its inﬂuence on this balance.
Our conclusions that these polymorphisms are inde-
pendent markers of AAA might be strengthened by
following patients longitudinally and measuring Lp(a)
levels over time.
Aneurysmal disease is associated with atherosclerosis as
indicated by the prevalence of coronary artery disease, cere-
brovascular disease, and peripheral occlusive aortic disease
in our patient population. Our study cannot deﬁnitively
prove whether polymorphisms rs3781590 and rs4988300
LRP5 gene markers of atherosclerosis represent generic
or speciﬁc markers of the development of AAA. Indeed,
analysis of the association of polymorphisms with the
AAA in the subgroup of patients and controls without
other sites of atherosclerotic disease shows similar results,
suggesting that rs3781590 and rs4988300 polymorphisms
are speciﬁc markers of aneurysmal disease.
Our study did not show association of the LRP5 poly-
morphisms studied and, in particular, of polymorphisms
associated with AAA (rs3781590 and rs4988300) with
the aortic diameter, suggesting that these polymorphisms
do not affect AAA growth. Nevertheless, one of the limita-
tions of our study is its inadequacy to evaluate the inﬂuence
of the investigated polymorphisms on the progression of
the disease, as our study was conducted on patients
admitted to the observation of the Vascular Surgery Unit
for repair of the AAA.
In conclusion, data of this work identify two signiﬁ-
cant, speciﬁc, and independent genetic risk markers for
the onset of AAA and underline the crucial role of LRP5
gene in aneurysmal disease.AUTHOR CONTRIBUTIONS
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Supplementary Table I (online only). Genotype distribution and allele frequency of the rs312016, rs627174,
rs667126, rs556442, and rs3736228 LRP5 polymorphisms in AAA patients and control subjects
SNP
Genotypes (%)
Minor allele
frequency
Genotypes (%)
Minor allele
frequency PaPatients (n ¼ 423) Control subjects (n¼423)
LRP5
rs312016 TT (12.7) TC (42.1) CC (45.2) T ¼ 0.338 TT (11.4) TC (43.0) CC (45.6) T ¼ 0.328 .815
rs627174 CC (4.0) CT (27.7) TT (68.3) C ¼ 0.179 CC (3.8) CT (26.7) TT (69.5) C ¼ 0.172 .932
rs667126 CC (10.9) CT (42.3) TT (46.8) C ¼ 0.321 CC (10.7) CT (47.0) TT (42.3) C ¼ 0.342 .362
rs556442 TT (41.6) TC (46.8) CC (11.6) C ¼ 0.350 TT (43.0) TC (47.3) CC (9.7) C ¼ 0.333 .664
rs3736228 CC (65.3) CT (30.0) TT (4.7) T ¼ 0.198 CC (62.9) CT (31.4) TT (5.7) T ¼ 0.214 .708
AAA, Abdominal aortic aneurysm; LRP5, low-density lipoprotein receptor-related protein; SNP, single nucleotide polymorphism.
The genotype distributions of the seven polymorphisms respected the Hardy-Weinberg equilibrium in patients and controls. No signiﬁcant differences in the
genotype distributions between patients and controls were observed for the LRP5 polymorphisms rs312016, rs627174, rs667126, rs556442, and rs3736228.
aAccording to the additive model.
Supplementary Table II (online only). OR for the occurrence of AAA according to rs4988300 and rs3781590 LRP5
polymorphisms in the subgroups of AAA patients and controls without other localizations (coronary artery disease,
cerebrovascular disease, and peripheral arterial occlusive disease) of atherosclerotic disease
Variables OR (95% CI) P
LRP5 rs4988300
T allele
1.45 (1.01-2.60) .049
LRP5 rs3781590
T allele
1.98 (1.036-3.78) .039
AAA, Abdominal aortic aneurysm; CI, conﬁdence interval; LRP5, low-density lipoprotein receptor-related protein; OR, odds ratio.
Multiple logistic regression analysis adjusted for traditional cardiovascular risk factors.
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Volume 58, Number 4 Galora et al 1068.e1Supplementary Table III (online only). Effect of the rs4988300 and rs3781590 LRP5 polymorphisms on the aortic
diameter in AAA patients and control subjects
LRP5
polymorphism
Patients (n ¼ 423) aortic diameter,
median (range), mm P
Control subjects (n ¼ 423) aortic
diameter, median (range), mm P
rs4988300
TTþGT 50 (31-91) .953 19 (12-47) .294
GG 50 (32-98) 18 (12-43)
rs3781590
TTþCT 50 (32-98) .206 19 (12-31) .862
CC 50 (31-91) 19 (12-47)
AAA, Abdominal aortic aneurysm; LRP5, low-density lipoprotein receptor-related protein.
